Cervical cancer and its precursor lesions cause significant morbidity and mortality for women, both in the United States and elsewhere. The association of cervical cancer and infection with certain types of human papillomaviruses (HPVs) has been recognized for some time; however, it is clear that HPV infection alone is insufficient to bring about the fully malignant phenotype. Clues to the mechanisms by which HPVs contribute to cervical tumorigenesis have been elucidated by studies demonstrating interaction between HPV oncoproteins (E6 and E7) and tumor suppressor gene products (p53 and pRB). However, the functional consequences of these interactions in the HPV-infected cell remain poorly understood. Furthermore, additional genetic alterations required for cervical tumor development and progression have yet to be fully characterized. Genetic and molecular approaches will he used to accomplish the following specific aims: 1) To map functional domains of the E6 proteins of high- and low-risk HPVs with respect to p53 binding and degradation in living cells. E6 genes mutated in the regions encoding p53 binding and degradation functions will be expressed in mammalian cells and analyzed for effects on the p53- dependent DNA damage response. 2) To use HPV E6-53 and E7-pRB interactions as tools to identify additional genes in the DNA damage response pathway. mRNA Differential Display (mDD) technology will be used to identify and clone candidate genes underlying p53 dependent G1 arrest, by comparison of gene expression patterns in cells with an intact response and in cells in which the pathway has been disrupted by HPV16 E6 and/or E7 expression. 3) To examine the effect of HPV E6 and E7 expression on integration of exogenously introduced DNA as a model of viral integration during cervical tumorigenesis. Cell lines expressing E6 and E7 proteins of high-vs. low- risk HPVs will be transfected with a reporter plasmid (pHyGal) encoding hygromycin resistance and scored for differences in frequency of stable integration of the test plasmid. 4) To identify other genes involved, in cervical tumor progression. DNA sequences involved in a rearrangement associated with progression from the well to poorly differentiated state in a primary cervical carcinoma will be cloned and characterized. mDD will he used to identify genes differentially expressed in tumors with well and poorly differentiated components and in pre-invasive versus invasive neoplasms. The proposed studies should provide new insights into the molecular pathogenesis of cervical cancer. Because HPV infection is likely to be an initiating event in the development of most cervical cancers, understanding the functional consequences of HPV infection in cervical epithelial cells may eventually lead to more effective treatment strategies for cervical cancer patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29CA064466-04
Application #
2683571
Study Section
Pathology B Study Section (PTHB)
Program Officer
Wong, May
Project Start
1995-04-01
Project End
1998-08-31
Budget Start
1998-04-01
Budget End
1998-08-31
Support Year
4
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Pathology
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Wu, R; Connolly, D; Ngelangel, C et al. (2000) Somatic mutations of fibroblast growth factor receptor 3 (FGFR3) are uncommon in carcinomas of the uterine cervix. Oncogene 19:5543-6
Connolly, D C; Greenspan, D L; Wu, R et al. (2000) Loss of fhit expression in invasive cervical carcinomas and intraepithelial lesions associated with invasive disease. Clin Cancer Res 6:3505-10
Wu, R; Connolly, D C; Dunn, R L et al. (2000) Restored expression of fragile histidine triad protein and tumorigenicity of cervical carcinoma cells. J Natl Cancer Inst 92:338-44
Tashiro, H; Blazes, M S; Wu, R et al. (1997) Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 57:3935-40
Greenspan, D L; Connolly, D C; Wu, R et al. (1997) Loss of FHIT expression in cervical carcinoma cell lines and primary tumors. Cancer Res 57:4692-8
Kessis, T D; Connolly, D C; Hedrick, L et al. (1996) Expression of HPV16 E6 or E7 increases integration of foreign DNA. Oncogene 13:427-31
Isacson, C; Kessis, T D; Hedrick, L et al. (1996) Both cell proliferation and apoptosis increase with lesion grade in cervical neoplasia but do not correlate with human papillomavirus type. Cancer Res 56:669-74
Kim, Y T; Thomas, N F; Kessis, T D et al. (1996) p53 mutations and clonality in vulvar carcinomas and squamous hyperplasias: evidence suggesting that squamous hyperplasias do not serve as direct precursors of human papillomavirus-negative vulvar carcinomas. Hum Pathol 27:389-95
Kessis, T D; Silberman, M A; Sherman, M et al. (1996) Rapid identification of patient specimens with microsatellite DNA markers. Mod Pathol 9:183-8